U ntil recently, no treatments were available to help slow the progression of metabolic dysfunction–associated steatohepatitis (MASH), a severe form of fatty liver disease. But in March 2024, a ...

I really didn't see the death of short-acting beta-agonists (SABAs) coming. Sure, I'd read the SYGMA trials, [1,2] and yes, I was aware of lobbying from the "other side of the pond" (Europe). [3] So I ...

This week, Dr Ray O’Connor takes a look at recent clinical articles on the management of asthma, and what environmental ...

A recent systematic review evaluated 19 randomized placebo-controlled trials of long-acting beta-agonist (LABA) use for at least three months in 33,826 patients with asthma (Ann Intern Med.

Long-acting beta agonists (LABAs) were associated with increased risk of asthma-related death, intubation, and hospitalization in a recent meta-analysis of individual patient data conducted by the FDA ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Please provide your email address to receive an email when new articles are posted on . Patients with asthma saw a 23% reduction in FeNO with treatment. Most adverse events were mild, with no serious ...

Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen and over 40 percent of academic pulmonary and allergy clinicians ...